The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1556
September 24, 2018
View Complete Issue         Table of Contents 2019 
Elagolix (Orilissa) - An Oral GnRH Antagonist for Endometriosis Pain
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Elagolix (Orilissa) - An Oral GnRH Antagonist for Endometriosis Pain
September 24, 2018 (Issue: 1556)
The FDA has approved elagolix (Orilissa – AbbVie), an oral gonadotropin-releasing hormone (GnRH) antagonist, for management of moderate to severe pain associated with endometriosis.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Elagolix (Orilissa) - An Oral GnRH Antagonist for Endometriosis Pain
Article code: 1556c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.